Fig. 5

Performance of the PM classifier on independent validation data. a Tumors of various types from COSMIC v70 (n = 1669). b Metastatic breast tumors from the SAFIR01 trial (n = 91). c Multiregion-sequenced non-small cell lung cancer (n = 9). See Fig. 3b legend. For comparison, the expected performance of our method in each data set was estimated according to the distribution of primary sites and the site-specific accuracies on test data